Please use this identifier to cite or link to this item:
|Title:||Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group||Authors:||Kim, S.J.
Hepatitis B virus
|Issue Date:||Nov-2013||Citation:||Kim, S.J., Hsu, C., Song, Y.-Q., Tay, K., Hong, X.-N., Cao, J., Kim, J.S., Eom, H.S., Lee, J.H., Zhu, J., Chang, K.-M., Reksodiputro, A.H., Tan, D., Goh, Y.T., Lee, J., Intragumtornchai, T., Chng, W.-J., Cheng, A.-L., Lim, S.T., Suh, C., Kwong, Y.-L., Kim, W.S. (2013-11). Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer 49 (16) : 3486-3496. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejca.2013.07.006||Abstract:||Background Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas. Methods Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n = 340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n = 127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis. Results HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving antiviral prophylaxis than those not (22.9%, 32/140 versus 59.1%, 13/22; p < 0.001). Lamivudine was most commonly used (96/162, 59.3%), but more than 20% of HBsAg-positive patients showed breakthrough HBV reactivation. In the cross-sectional analysis, a reduced rate of HBV reactivation occurred for entecavir as compared with lamivudine prophylaxis (6.3% versus 39.3%; p < 0.05). HBV DNA monitoring of HBsAg-negative/HBcAb-positive patients in the cross-sectional analysis showed HBV reactivation in only 2.4% of cases. Conclusions This is the largest study of HBV reactivation in patients receiving rituximab-containing chemotherapy to date, and we defined the probability of HBV reactivation in an HBV-endemic region. © 2013 Elsevier Ltd. All rights reserved.||Source Title:||European Journal of Cancer||URI:||http://scholarbank.nus.edu.sg/handle/10635/126815||ISSN:||09598049||DOI:||10.1016/j.ejca.2013.07.006|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.